[Determination of functional activity of lymphocytes in patients with tuberculosis and in patients of group IIIA of clinic registries by electrophoretic mobility].

Morozova TI, Khudzik LB, Tikhomirova LA

Problemy tuberkuleza1 Jan 1994

PMID8036219PepBankPUB-08036219

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Thymalin aloneNon-randomized trialSafety outcome
In clinically cured tuberculosis patients, thymic immunomodulators including thymalin improved tolerance of antirecurrent chemotherapy.
In plain wordsIn people clinically cured of tuberculosis, immune drugs including thymalin improved tolerance of chemotherapy to prevent recurrence.
Peptide
Thymalin
Outcome
IncreaseAntirecurrent chemotherapy tolerance
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
2 context sentences(design, population, supporting numbers)
Summary · context
The electrophoretic mobility of peripheral blood lymphocytes was studied in 35 patients with pulmonary tuberculosis, 128 persons clinically cured of tuberculosis, and 30 healthy persons by using an Elphor-VaP-5 apparatus (Germany).
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0803621901
02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In clinically cured tuberculosis patients, thymic immunomodulators including thymalin stimulated T-lymphocyte functional activity.
In plain wordsIn people clinically cured of tuberculosis, immune drugs including thymalin increased T-lymphocyte activity.
Peptide
Thymalin
Outcome
IncreaseT-lymphocyte functional activity
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
2 context sentences(design, population, supporting numbers)
Summary · context
The electrophoretic mobility of peripheral blood lymphocytes was studied in 35 patients with pulmonary tuberculosis, 128 persons clinically cured of tuberculosis, and 30 healthy persons by using an Elphor-VaP-5 apparatus (Germany).
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0803621902
03HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In clinically cured tuberculosis patients, thymic immunomodulators including thymalin stimulated B-lymphocyte functional activity.
In plain wordsIn people clinically cured of tuberculosis, immune drugs including thymalin increased B-lymphocyte activity.
Peptide
Thymalin
Outcome
IncreaseB-lymphocyte functional activity
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
2 context sentences(design, population, supporting numbers)
Summary · context
The electrophoretic mobility of peripheral blood lymphocytes was studied in 35 patients with pulmonary tuberculosis, 128 persons clinically cured of tuberculosis, and 30 healthy persons by using an Elphor-VaP-5 apparatus (Germany).
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0803621903
04HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialSafety outcome
In persons in registry group IIIA, thymic immunomodulators including thymogen improved tolerance of antirecurrent chemotherapy.
In plain wordsIn people in registry group IIIA, immunomodulators including thymogen improved tolerance of preventive chemotherapy.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseTolerance of antirecurrent chemotherapy
Study
n: not reported in source
Clinically cured tuberculosis with residual changes
Outcome group
Adverse events · Whole body
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0803621904
05HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialActivity measurement
In persons in registry group IIIA, thymic immunomodulators including thymogen stimulated T lymphocyte functional activity.
In plain wordsIn people in registry group IIIA, immunomodulators including thymogen increased T-cell activity.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseT lymphocyte functional activity
Study
n: not reported in source
Clinically cured tuberculosis with residual changes
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0803621905
06HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialActivity measurement
In persons in registry group IIIA, thymic immunomodulators including thymogen stimulated B lymphocyte functional activity.
In plain wordsIn people in registry group IIIA, immunomodulators including thymogen increased B-cell activity.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseB lymphocyte functional activity
Study
n: not reported in source
Clinically cured tuberculosis with residual changes
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Immunomodulators improved the tolerance of antirecurrent chemotherapy in persons with IIIA dispensary register group and produced a marked stimulating effect on the functional activity of T and B lymphocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
This study revealed abnormal lymphocytic functional activity both in patients with tuberculosis and in patients with great residual changes after prior tuberculosis, which was the basis for using of thymic immunomodulators (thymalin or thymogen) in the latters.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0803621906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 12:50 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

[Determination of functional activity of lymphocytes in patients with tuberculosis and in patients of group IIIA of clinic registries by electrophoretic mobility].

Summary

Results from this study6

Studies that did not test the peptide alone6

Version history

Subjects

Publication types

MeSH terms